Cytokinetics Inc (CYTK)

11.25
NASDAQ : Health Care
Prev Close 11.30
Day Low/High 10.55 / 11.94
52 Wk Low/High 6.00 / 13.45
Avg Volume 299.60K
Exchange NASDAQ
Shares Outstanding 40.52M
Market Cap 457.84M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Biotech Premarket Movers: Cytokinetics, Artana Therapeutics, Bluebird

Shares of late-stage biopharma Cytokinetics increased following positive comments from an Needham analyst.

Interesting CYTK Put And Call Options For August 18th

Interesting CYTK Put And Call Options For August 18th

Investors in Cytokinetics Inc saw new options begin trading this week, for the August 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 196 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen

Cytokinetics, Achillion and Qiagen were among the biotech stock movers in premarket trading on Thursday.

Commit To Purchase Cytokinetics At $8, Earn 15.8% Annualized Using Options

Commit To Purchase Cytokinetics At $8, Earn 15.8% Annualized Using Options

Investors considering a purchase of Cytokinetics Inc stock, but cautious about paying the going market price of $10.40/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $8 strike, which has a bid at the time of this writing of $1.10.

Cytokinetics Stock Sees Short Interest Decline 11%

Cytokinetics Stock Sees Short Interest Decline 11%

The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 387,607 share decrease in total short interest for Cytokinetics Inc , to 3,108,691, a decrease of 11.09% since 10/14/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cytokinetics Announces Publication Relating To Novel Smooth Muscle Myosin Inhibitor

Cytokinetics Announces Publication Relating To Novel Smooth Muscle Myosin Inhibitor

Discovery of Novel Binding Mechanism Has Potential to Guide Design of Myosin Inhibitors

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABEV, ARLP, BHI, CYTK, MET, MGI, OSB, PBFX, SGEN, SPKE Downgrades: APO, CBL, CTS, FORM, ILG, NKSH, SPCB, TRS, TUES Initiations: CSWI Read on to get TheStreet Quant Ratings' detailed report:

First Week of May 2017 Options Trading For Cytokinetics (CYTK)

First Week of May 2017 Options Trading For Cytokinetics (CYTK)

Investors in Cytokinetics Inc saw new options begin trading this week, for the May 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 200 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Cytokinetics Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv

Cytokinetics Announces First Patient Enrolled In VIGOR-ALS, An Open-Label Extension Clinical Trial Of Tirasemtiv

Eligible Patients Have Completed Participation in Phase 3 Clinical Trial VITALITY-ALS

Commit To Buy Cytokinetics At $7, Earn 12.4% Annualized Using Options

Commit To Buy Cytokinetics At $7, Earn 12.4% Annualized Using Options

Investors eyeing a purchase of Cytokinetics Inc shares, but cautious about paying the going market price of $9.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $7 strike, which has a bid at the time of this writing of 55 cents.

Cytokinetics Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas

Cytokinetics Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Expanded Collaboration With Astellas

Clearance Triggers $65 Million Upfront Cash Payment in Addition to $30 Million in Sponsored Research & Development Funding Through 2017

Short Interest Drops 28.6% For CYTK

Short Interest Drops 28.6% For CYTK

The most recent short interest data has been released for the 09/15/2016 settlement date, which shows a 1,457,024 share decrease in total short interest for Cytokinetics Inc , to 3,640,233, a decrease of 28.58% since 08/31/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Cytokinetics Announces Presentation Of Additional Results From COSMIC-HF At The HFSA Annual Scientific Meeting

Cytokinetics Announces Presentation Of Additional Results From COSMIC-HF At The HFSA Annual Scientific Meeting

Data Show Treatment with Omecamtiv Mecarbil May Improve Patient Symptoms at 20 Weeks